The two companies are merging after previously filing for bankruptcy due to opioid-related litigation and financial losses.

Mallinckrodt and Endo , drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced ...

The Mallinckrodt-Endo combination will have approximately 5,700 employees at closing, as well as 17 manufacturing facilities, 30 distribution centers, and an operating footprint primarily located in ...

Mallinckrodt and Endo are merging in a $6.7 billion deal, with a pro forma NYSE listing and $900 million in financing.

The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic ...

Endo shareholders will get $80 million in cash and own 49.9% of the combined company, while Mallinckrodt shareholders will ...

Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York ...

Wachtell, Lipton, Rosen & Katz is steering Mallinckrodt Pharmaceuticals and Davis Polk & Wardwell is guiding Endo Inc. in ...

will combine their branded drugs businesses that include Endo's testosterone injection Aveed as well as Mallinckrodt's Acthar Gel and kidney disease therapy Terlivaz. Advt The merger will "create ...

Wilmington, Delaware-- (Newsfile Corp. - March 13, 2025) - Rigrodsky Law, P.A. is investigating Endo, Inc. ("Endo") (OTC: NDOI) regarding possible breaches of fiduciary duties and other violations of ...

Pharmaceutical leaders Mallinckrodt plc and Endo, Inc. (OTCQX: NDOI) have entered an agreement to merge, creating a global, ...

The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...